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Abstract: Disturbed lipid metabolism is a well-established feature of human Alzheimer’s disease (AD). The present 
study used gas chromatography-mass spectrometry (GC-MS) analysis of fatty acid methyl esters (FAMES) to profile 
all detectable fatty acid (FA) species present in post-mortem neocortical tissue (Brodmann 7 region). Quantitative 
targeted analysis was undertaken from 29 subjects (n=15 age-matched controls; n=14 late-stage AD). GC-MS anal-
ysis of FAMES detected a total of 24 FAs and of these, 20 were fully quantifiable. The results showed significant 
and wide ranging elevations in AD brain FA concentrations. A total of 9 FAs were elevated in AD with cis-13,16-
docosenoic acid increased most (170%; P=0.033). Intriguingly, docosahexanoic acid (DHA; C22:6) concentrations 
were elevated (47%; P=0.018) which conflicts with the findings of others (unaltered or decreased) in some brain 
regions after the onset of AD. Furthermore, our results appear to indicate that subject gender influences brain FA 
levels in AD subjects (but not in age-matched control subjects). Among AD subjects 7 FA species were significantly 
higher in males than in females. These preliminary findings pinpoint FA disturbances as potentially important in the 
pathology of AD. Further work is required to determine if such changes are influenced by disease severity or differ-
ent types of dementia. 
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Introduction 
Alzheimer’s disease (AD) is a neurodegenera-
tive disorder characterised by progressive 
memory loss and deteriorating cognitive abili-
ties in older populations. Currently dementia 
affects 820,000 people in the UK [1] and 
recent global projections suggest that the num-
ber of people affected by AD will triple to 115 
million by the year 2050 [2]. The main patho-
logical hallmarks of AD are the accumulation of 
β-amyloid plaques, and neurofibrillary tangles 
[3, 4]. Despite numerous studies that have 
been conducted on these two histological fea-
tures, the cause, onset and development of the 
disease needs to be fully elucidated. Current 
therapeutic options temporarily slow the pro-
gression of symptoms for approximately 6-12 
months but no disease-modifying treatments 
are currently available [5]. Lipid profiling (lipido-
mic) techniques are increasingly being used 
to study AD in the hope of finding new mecha-
nistic insights or novel diagnostic biomarkers 
[6]. The application of lipidomic tools can reveal 
alterations in lipid metabolism [6-8], lipid-me- 
diated signaling processes [6, 9, 10], biochemi-
cal interaction with other lipids, proteins and 
metabolites [11, 12]; and ultimately these tech-
niques could lead to new discoveries in terms 
of disease pathogenesis and pharmacological 
targets [13, 14]. 
Recent lipid profiling studies of AD brain and 
plasma reveal that many, if not all, classes of 
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lipids are affected by AD. Nitsch et al. [15] 
reported aberrant lipid metabolism and per-
turbed lipid composition in post-mortem brain 
tissue from pathologically confirmed AD cases. 
They described a global decrease in the con-
centration of phosphatidylcholine (PC) and 
increased levels of PC deacylation products 
[15]. Others have reported decreases of up to 
40% in the levels of plasmalogen-phosphatidyl-
ethanolamine (p-PE) in white brain matter in 
the early stages of AD [16]. There is increasing 
epidemiological and molecular evidence indi-
cating that cholesterol plays a role in the initia-
tion and/or progression of AD [17, 18]. Evidence 
suggests that disturbed cholesterol metabo-
lism and hypercholesterolemia are important 
factors in amyloid plaque formation and tau 
hyperphosphorylation [17]. Plasma levels of 
desmosterol (a precursor to cholesterol) have 
been suggested as a potential AD biomarker 
and correlates closely to Mini-Mental State 
Examination scores of AD subjects [19]. Other 
investigations report significant depletions in 
plasma sphingomyelin and increased levels of 
ceramide in AD patients, with the ratio of 
ceramides to sphingomyelins reported to be 
much more discriminatory in determining AD 
cases from controls than lipid-type alone [20]. 
Recent findings suggest significant depletions 
in plasma levels of 10 particular lipid molecules 
(including species of PCs, lyso-PCs, and acetyl-
carnitines) of individuals with mild cognitive 
impairment (MCI) at short-term risk of develop-
ing AD [21]. 
A review of the scientific literature indicates 
that only a small number of studies have exam-
ined changes in the brain FA complement fol-
lowing onset of AD. 50% of the neuronal mem-
brane is composed of polyunsaturated fatty 
acids (PUFA) [22]. These FA are shown to be 
incorporated into critical membrane phospho-
lipids and secondary signaling messengers 
that modulate neuronal well-being, oxidative 
stress and inflammation [22]. PUFAs in the 
brain include both long chained Omega-3 and 
Omega-6 FA. Several studies have shown that 
an Omega-3 PUFA, in particular docosahexa-
noic acid (DHA) has an anti-inflammatory effect 
within the brain [23]. High dietary intake of DHA 
is correlated with lower risk of developing neu-
rological disorders such as AD, Parkinson’s dis-
ease and major depression [24, 25]. In addi-
tion, aged mice supplemented with DHA and 
EPA (eicosapentaenoic acid) were found to 
attenuate pro-inflammatory cytokine expres-
sion and astrogliosis as well as restoring spa- 
tial memory deficits in the hippocampal region 
[26]. While omega-3 FAs assist in providing 
neuroprotective functions in aged and diseased 
brain, omega-6 FAs are known to result in the 
production of pro-inflammatory cytokines from 
arachidonic acid (AA). Studies have indicated 
that increased levels of pro-inflammatory cyto-
kines and activation of neutrophils were detect-
ed as a result of eicosanoid synthesis from 
enzymatic activity of cyclooxygenase and lipo-
oxygenase on AA [27].
The present study describes a targeted quanti-
tative method for profiling FAs in post-mortem 
human brain tissue (Brodmann 7 region) from 
late-stage AD patients and healthy, non-
demented, age-matched control subjects. The 
aims were to: 1) use GC-MS to quantify and 
identify all the detectable FA present in post-
mortem human brain tissue; and 2) to deter-
mine which of the FA were most significantly 
affected. 
Methods
Reagents and analytical standards
Fatty acid standards: myristic acid methyl est- 
er (C14:0), pentadecanoic acid methyl ester 
(C15:0) (PDA), palmitic acid methyl ester 
(C16:0), palmitoleic acid methyl ester (C16: 
1Δ9), margaric acid methyl ester (C17:0), cis-
10-heptadecanoic acid methyl ester (C17: 
1Δ10), stearic acid methyl ester (C18:0), elaidic 
acid methyl ester (t-C18:1Δ9), oleic acid methyl 
ester (C18:1Δ9), linolelaidic acid methyl ester 
(t-C18:2Δ9,12), linoleic acid methyl ester 
(C18:2Δ9,12), arachidic acid methyl ester 
(C20:0), linolenic acid methyl ester (C18: 
3Δ9,12,15), heneicosanoic acid methyl ester 
(C21:0), all-cis-11,14,17-eicosatrienoic acid 
methyl ester (C20:3Δ11,14,17), arachidonic 
acid methyl ester (C20:4Δ5,8,11,14), all-cis-
13,16-docosadienoic acid methyl ester (C22: 
2Δ13,16), lignoceric acid methyl ester (C24:0), 
nervonic acid methyl ester (C24:1Δ16,15), doc-
osahexanoic acid methyl ester/DHA (C22: 
6Δ4,7,10,13,16,19), gondoic acid methyl est- 
er (C20:1), all-cis-8,11,14-eicosatrienoic acid 
methyl ester (C20:3Δ8,11,14), erucic acid 
methyl ester (C22:1Δ13), all-cis-5,8,11,14,17-
eicosapentaenoic acid methyl ester/EPA (C20: 
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5Δ5,8,11,14,17), lauric acid methyl ester 
(C12:0), were all purchased from Sigma Aldrich 
(UK). Solvents including; methanol, n-Hexane 
and dichloromethane (DCM) were all CHRO- 
MASOLV grade for HPLC use and were bought 
from Sigma Aldrich (UK). Hydrogen chloride 
(1.25 M) in methanol was purchased from 
Fluka Analytical (UK).  
Brain tissue samples
Brain tissue for this study (Brodmann 7 region, 
neocortex region, n=15 Controls; n=14 AD) 
was provided by the Newcastle Brain Tissue 
Resource which is part of the Brains for 
Dementia Research (BDR) project. We selected 
the parietal cortex (Brodmann 7) region as it 
not the primary site of AD pathology. Studies 
have shown that FA composition of the parietal 
cortex is much less affected than other brain 
regions such as the frontal or temporal cortex 
[28]. Sample details including Braak stage, 
age, gender and post mortem delay can be 
found in Table 1.  
Frozen tissue samples were initially lyophiliz- 
ed and milled to a fine powder using the 
Freezer/Mill-cryogenic grinder (Model 6850, 
SPEX Sample PREP, UK). The use of liquid nitro-
gen throughout the milling process, avoids heat 
generation which often results in protein dena-
turation, or inadvertent increase of amino acids 
and changes in concentration of metabolites 
in the brain tissue samples. Once milled, all 
samples were stored at -80°C. The brain sam-
ples were extracted using the modified version 
of the Folch extraction procedure [29]. Briefly, 
50 mg (±0.5 mg) tissue samples were mixed 
thoroughly in 1 ml of 50% methanol:water in a 
2 ml sterile eppendorf tube using a Merris mini-
mix paint-shaker for 10 min then sonicated for 
15 min before centrifugation at 16,000 g at 
4°C for 20 min. The supernatant was kept and 
used to separately investigate the polar metab-
sent from all the samples. Lauric acid was 
added to each pellet (100 ng/uL) then FA were 
extracted in 1 ml of DCM (dichloromethane), 
transferred to sterile tubes and evaporated to 
dryness. FA were derivatised to fatty acid meth-
yl esters (FAMEs) by reconstitution in 2 ml 
hydrogen chloride (1.25 M) in methanol 
(HCL:MeOH) and heated for 1 h at 100°C. 
Samples were then cooled and 1 ml of water 
was added. The FAMEs were extracted in 1 ml 
of hexane and subsequently analyzed using an 
Agilent GC (model 7890, Delaware, USA) cou-
pled to an MS detector (Agilent model 5975C, 
Delaware, USA). Throughout the experiment, all 
samples were kept at 4°C to avoid denaturation 
of metabolic products. 
GC-MS analysis
Samples were injected (inlet temp 220°C, split-
mode ratio of 15:1) onto a CP-Sil88 fused silica 
capillary column (100 m x 0.25 mm x 0.25 μm) 
(Agilent, UK) with helium as carrier gas at a con-
stant flow of 1 ml/min. The initial temperature 
gradient started at 100°C, increasing at 4°C/
min to 220°C and was then held for 5 min. 
Following this, the gradient increased at 4°C/
min to 240°C and was held for 8 min. The Mass 
Selective Detector (MSD) operated at 70eV in 
dual Scan/Selected Ion monitoring (SIM) mode 
the Source temp was 230°C the Quad temp 
150°C and the Interface temp 225°C. The full 
scan ranged from m/z 50-550, whilst SIM 
mode targeted the molecular ion and another 
appropriate ion selected from the fragmenta-
tion pattern, each ion having a dwell time of 
100 ms. All detectable FAMEs were confirmed 
using purchased analytical-grade standards 
and led to targeted analysis involving 24 FA. 
The quantification was based on a linear regres-
sion model formed from five point scaling fac-
tors of individual fatty acid methyl esters that 
were either conducted at a low (0-20 ng/ml) or 
high concentration range (0-300 ng/ml). The 
Table 1. Descriptive characteristics of the study population by 
group. Age and post-mortem delay are presented as mean (±SEM)
Age-matched
control (n=15)
Late-stage
AD (n=14)
Age (years) 77.9±3.03 86±1.89
Female/Male 11/4 6/8
Post-mortem delay (hours) 45.3±6.96 45.2±6.25
Braak Stage, n (0/1/2/3/4/5/6) (3/2/6/3/1/0/0) (0/0/0/0/0/2/12)
olome (as described by Gra- 
ham et al. [5]). The remaining 
pellet (which contained >95% 
of the lipid content) was stored 
in a -20°C freezer for 6 months 
and subsequently under went 
FA profiling. Lauric acid (C12:0) 
was selected as an internal 
standard because it was iden-
tified as being completely ab- 
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GC-MS was initially auto-tuned using PTFBA 
and the built-in MSDCHEM software to check 
the efficiency of the machine prior to running 
the experiment. Lauric acid was used as both 
the internal standard control for all the fatty 
acids as well as a measuring standard to detect 
changes in injection volume for all the extract-
ed samples. Hexane was used as blank in the 
experiment. FA concentrations are reported as 
(g/kg post-mortem (PM) human brain dry 
weight) and corrected to the internal standard. 
Fatty acids with calibration curves of poor lin-
earity (R2 ≤ 0.9) were not quantified.
Data analysis 
Integration and quantitation of individual FA 
peaks from the GC-MS analysis was done using 
the MSD ChemStation Software (Agilent Tech- 
nologies, USA). A one-tailed homoscedastic Stu- 
dent’s T-test was undertaken to calculate the 
significant differences (Microsoft Excel, US). 
Results are presented as mean values ± stan-
dard deviation (SD). Graphical representations 
were produced using Prism (GraphPad 5.0, 
California, USA). 
Results 
A number of changes in FA concentrations in 
the neocortex region (Brodmann area 7) of AD 
patients were observed compared with Con- 
trols. Figure 1 shows a typical Total Ion 
Chromatogram (TIC) of brain FAMEs following 
separation on a CP-Sil88 column. Out of 24 
individual FA that were detectable in both 
groups, 20 were accurately quantified, of which 
9 were significantly different (p<0.05) between 
AD patients and healthy age-matched controls 
(Table 2). There was a general trend towards 
increased FA levels in AD samples, however the 
total FA levels did not differ between groups 
Table 2. FA measurements in post-mortem brain samples of Brodmann 7 region from Control and 
late-stage AD subjects
Fatty Acid Lipid No. RT R2 Mass Control(n=15)
AD
(n=14) P-Value
Myristic acid C14:0 23.16 0.987 242.22 0.022±0.107 0.268±0.068 0.085
Pentadecanoic acid   C15:0 24.91 0.991 256.42 0.043±0.023 0.058±0.020 0.035*
Palmitic acid   C16:0 26.60 0.991 270.45 8.914±3.995 11.18±2.588 0.042*
Palmitoleic acid  C16:1Δ9 27.77 0.991 268.43 4.561±2.834 6.349±2.168 0.034*
Heptadecanoic acid  C17:0 28.21 0.989 284.48 0.091±0.049 0.124±0.040 0.029*
cis-10-heptadecenoic acid  C17:1Δ10 29.30 0.989 282.46 0.539±0.405 0.716±0.267 0.090
Stearic acid  C18:0 29.79 0.986 298.50 8.390±4.097 10.65±2.788 0.048*
Elaidic acid  t-C18:1Δ9 30.71 0.986 296.49 5.392±2.662 7.639±3.242 0.025*
Oleic acid  c-C18:1Δ9 30.82 0.988 297.49 7.968±4.179 9.781±3.243 0.103
Linolelaidic acid  t-C18:2Δ9,12 31.29 0.986 294.47 0.030±0.013 0.031±0.014 0.425
Linoleic acid  c-C18:2Δ9,12 32.38 0.987 294.47 0.337±0.196 0.407±0.176 0.160
Arachidic acid  C20:0 32.85 0.973 326.56 0.050±0.028 0.060±0.023 0.145
Linolenic acid  C18:3Δ9,12,15 34.20 0.987 294.26 0.762±0.369 0.874±0.314 0.194
Heneicosanoic acid  C21:0 34.39 0.974 340.58 0.023±0.005 0.021±0.003 0.167
all-cis-11,14,17-eicosatrienoic acid C20:3Δ11,14,17 28.93 0.917 320.51 0.173±0.198 0.319±0.204 0.031*
Arachidonic acid  C20:4Δ5,8,11,14 38.08 0.983 318.49 1.929±1.322 2.582±0.934 0.069
all-cis-13,16-docosadienoic acid C22:2Δ13,16 38.89 0.946 350.58 0.021±0.031 0.045±0.038 0.033*
Lignoceric acid  C24:0 39.55 0.965 382.66 2.317±1.461 2.370±1.220 0.458
Nervonic acid  C24:1Δ15 40.68 0.968 380.65 0.664±0.504 0.724±0.724 0.398
Docosahexanoic acid C22:6Δ4,7,10,13,16,19 45.01 0.925 342.51 4.897±2.810 7.215±2.818 0.018*
Gondoic acida C20:1Δ11 34.04 0.475 324.54
all-cis-8,11,14-eicosatrienoic acida C20:3Δ8,11,14 37.05 0.745 320.51
Erucic acida C22:1Δ13 35.60 0.267 352.59
Eicosapentanoic acida C20:5Δ5,8,11,14,17 39.85 0.019 316.24
Lauric acid (internal standard) C12:0 19.57 0.996 214.34
Total FA content 47.12±25.29 61.41±20.90 0.058
FA concentrations (g/kg dry weight) are displayed as mean ± SD. *p<0.05 for Control vs AD. aFA not quantified due to poor calibration curves (R2 
less than 0.9).
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(P=0.058). All the measured FA are listed as 
Table 2 and include the 9 FA found to be signifi-
cantly different between AD and controls. 
Figure 2 shows those FA which are significantly 
different between AD and control samples. It 
highlights that AD tissue has higher concentra-
tions of cis-13,16-docosadienoic acid (170%), 
cis-11,14,17-docosatrienoic acid (132%), doco-
sahexanoic acid (DHA) (47%), elaidic acid (41%), 
palmitoleic acid (39%), heptadecanoic acid 
(36%), pentadecanoic acid (35%) and palmitic 
acid (25%) when compared with control PM 
brain tissue. Despite numerous reports which 
have shown a significant decrease or unaltered 
levels of DHA in different brain regions, our 
accurately quantified results have found DHA 
at significantly (p<0.05) higher concentrations 
in AD patients (47%) (Figure 2). When PM 
human brain tissue from male and female 
specimens are compared for both AD and con-
trol samples it was found that 7 FA were found 
at significantly (p<0.05) higher concentrations 
in male AD tissue (Table 3). These included cis-
13,16-docosadienoic acid (170%), myristic acid 
(35%), stearic acid (33%), and palmitic acid 
(33%) as displayed in Figures 3 and 4.
Discussion 
This study has comprehensively quantified FAs 
detectable by GC-MS in human post-mortem 
brain tissue from AD and control patients. 
Having established the FA composition of PM 
brain tissue, detailed quantification studies 
were conducted across the tissue samples 
from 29 subjects, comprising 14 individuals 
with late-stage AD and 15 age-matched control 
subjects. The findings indicate that the FA com-
plement of brain neocortex tissue is profoundly 
affected by late-stage AD (Braak stages 5-6). A 
general trend towards increased concentra-
Figure 1. GC-MS detection of brain FA. Peaks were postiviely identified as: 1. lauric acid, 2. myristic acid, 3. pen-
tadecanoic acid, 4. palmitic acid, 5. palmitoleic acid, 6. heptadecanoic acid, 7. cis-10-heptadecanoic acid, 8. stearic 
acid, 9. elaidic acid, 10. oleic acid, 11. linolelaidic acid, 12. linoleic acid, 13. arachidic acid, 14. cis-11-eicosanoic 
acid, 15. linolenic acid, 16. heneicosanoic acid, 17. cis-8,11,14-eicosatrienoic acid; 18. erucic acid, 19. cis-11,14,17-
eicosatrienoic acid, 20. arachidonic acid, 21. cis-13,16-docosadienoic acid, 22. lignoceric acid, 23. Eicosapenta-
noic acid 24. nervonic acid, 25. Docosahexaenoic acid.
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tions of a wide range of FAs was observed in AD 
tissue. Of the 24 detectable fatty acids 20 were 
accurately quantified, and of these 9 were sig-
nificantly different between AD patients and 
healthy non-demented age-matched controls. 
Samples from late-stage AD subjects had high-
er concentrations of cis-13,16-docosadienoic 
acid (170%), cis-11,14,17-docosatrienoic acid 
(132%), docosahexanoic acid (DHA) (47%), 
elaidic acid (41%) palmitoleic acid (39%), hep-
tadecanoic acid (36%), pentadecanoic acid 
(35%) and palmitic acid (25%) compared with 
controls (Figure 2). Previous reports found DHA 
levels to be either significantly decreased (mid-
frontal and superior temporal cortex) [30] or 
unaltered (frontal, temporal and parietal neo-
cortex) [31] in AD subjects. However, we report 
DHA concentrations to be significantly higher in 
the Brodmann 7 region of AD PM brain tissue 
(47%). 
A particularly noteworthy aspect of our findings 
was the influence that subject gender had on 
FA concentrations in AD tissue. Analysis of 
brain tissue from male and female specimens 
found that 7 FAs were significantly higher in 
male AD subjects (Table 3). These included cis-
13,16-docosadienoic acid (170%), linoleic acid 
(63%), arachidonic acid (50%), heptadecanoic 
acid (37%), myristic acid (35%), stearic acid 
(33%), and palmitic acid (33%; Figure 3). This 
could indicate that the lipidome of male and 
female subjects responded differently to the 
development of AD pathology. However, these 
findings should be treated with caution given 
the relatively small sample size (n=8 male AD; 
n=7 female AD). Despite this, it is worth noting 
that in healthy subjects no significant FA chang-
es were observed and therefore further exami-
nation of gender-related differences in brain FA 
in AD is warranted. Whilst the reason for such 
differences are yet to be determined, the study 
of FA compositions in different regions of the 
brain thus far has yet to record any association 
between FA and gender [28] making the first 
time this has been reported. 
Figure 2. FAs (g/kg) significantly altered between Control and AD. A total of 9 brain FFA from the 24 measured 
(Table 1) were significantly elevated in late-stage AD. FFA concentrations are displayed as mean ± SD. *p<0.05 was 
deemed statistically significant.
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Omega-3 and -6 (n-3/n-6) (linolenic and linole-
ic) FAs are essential fatty acids [32, 33]. They 
are obtained from the diet given that the human 
body cannot naturally synthesize them and act 
as precursors for the synthesis of other fatty 
acids through a series of saturation and elon-
gation reactions [32]. Both n-3 and n-6 FAs 
have been implicated in the modulation of brain 
inflammatory processes [34-38]. The signifi-
cant increase in cis-13,16-docosadienoic con-
centrations observed here could form part of 
an anti-inflammatory response to the develop-
ment of AD. Inflammation is one of many hall-
marks of AD as found in a number of different 
studies including elevated levels of pro-inflam-
matory cytokines and activated microglia in AD 
patients [39, 40]. Fatty acids such as arachi-
donic acid (AA; C20:4), eicosapentanoic acid 
(EPA; C20:5) and DHA are thought to modulate 
the severity and duration of AD inflammatory 
processes [41, 42]. These fatty acids exert 
their inflammatory function through their con-
version to potent eicosanoids such as prosta-
glandins, thromboxanes and leukotrienes (by 
AA), or resolvins and docosatrienes (by EPA and 
DHA) by means of cyclooxygenase (COX) and/or 
lypooxygenase (LOX) enzymes [32, 33]. Eicosa- 
noids derived from AA are normally pro-inflam-
matory. Studies have indicated that increased 
levels of pro-inflammatory cytokines and acti-
vation of neutrophils were detected as a result 
of eicosanoid synthesis from enzymatic activity 
of COX and LOX on AA [27]. In the present study 
neither AA nor EPA significantly differed be- 
tween AD and control subjects. However, if only 
male AD patients and male controls were com-
pared AA was significantly (P<0.05) higher. 
Increased levels of cis-13,16-docosadienoic 
concentrations could provide neuroprotection 
by blocking COX enzyme activity [34]. Henry et 
al. [43] investigated fatty acids for COX inhibi-
tion, finding cis-13,16-docosadienoic acid and 
two other fatty acids to be potent inhibitors 
[43]. This supports the notion that cis-
13,16-docosadienoic acid could be part of an 
anti-inflammatory mechanism to reduce the 
severity of inflammation in AD.
Reported studies are somewhat conflicting 
regarding the relationship between DHA levels 
and AD. Two studies reported brain DHA to be 
unchanged in AD [31] and another found it to 
be lower [30, 44]. Here we observed a 47% 
increase in DHA in AD subjects (Figure 2). 
Table 3. FA concentrations (g/kg dry weight) in post-mortem brain samples of Brodmann 7 region of 
Control and late-stage AD, male and female subjects
Fatty Acid Lipid No.
Control AD
Male (n=4) Female (n=11) P-value Male (n=8)
Female 
(n=7) P-value
Myristic acid   C14:0 0.252±0.106 0.208±0.111 0.254 0.301±0.058 0.223±0.055 0.013*
Pentadecanoic acid   C15:0 0.052±0.018 0.040±0.025 0.192 0.066±0.016 0.049±0.022 0.058
Palmitic acid   C16:0 9.368±3.152 8.479±4.388 0.401 12.54 ±1.225 9.373±2.903 0.008*
Palmitoleic acid  C16:1Δ9 5.438±2.152 4.242±3.072 0.245 6.637±2.294 5.966±2.131 0.294
Heptadecanoic acid  C17:0 0.104±0.039 0.086±0.053 0.278 0.141±0.023 0.102±0.048 0.035*
cis-10-Heptadecenoic acid  C17:1Δ10 0.596±0.403 0.519±0.424 0.378 0.777±0.186 0.634±0.349 0.170
Stearic acid  C18:0 8.799±3.400 8.241±4.466 0.413 11.92±1.231 8.953±3.471 0.022*
Elaidic acid  t-C18:1Δ9 5.154±3.350 5.478±2.554 0.422 8.313±3.132 6.739±3.449 0.195
Oleic acid  c-C18:1Δ9 8.201±3.579 7.884±4.537 0.451 10.95±2.726 8.224±3.441 0.062
Linolelaidic acid  t-C18:2Δ9,12 0.023±0.010 0.032±0.014 0.141 0.030±0.016 0.032±0.012 0.413
Linoleic acid  c-C18:2Δ9,12 0.379±0.189 0.322±0.206 0.320 0.489±0.185 0.299±0.088 0.020*
Arachidic acid  C20:0 0.054±0.031 0.048±0.028 0.369 0.065±0.016 0.053±0.030 0.177
Linolenic acid  C18:3Δ9,12,15 0.918±0.542 0.705±0.300 0.171 0.962±0.290 0.757±0.332 0.121
Heneicosanoic acid  C21:0 0.021±0.002 0.023±0.006 0.266 0.021±0.003 0.021±0.003 0.355
all-cis-11,14,17-eicosatrienoic acid C20:3Δ11,14,17 0.204±0.198 0.162±0.206 0.363 0.371±0.159 0.249±0.248 0.142
Arachidonic acid  C20:4Δ5,8,11,14 1.915±0.580 1.935±1.532 0.490 3.014±0.777 2.006±0.851 0.020*
all-cis-13,16-Docosadienoic acid  C22:2Δ13,16 0.017±0.021 0.022±0.035 0.400 0.062±0.038 0.023±0.027 0.026*
Lignoceric acid  C24:0 2.303±1.693 2.322±1.459 0.492 2.531±0.930 2.154±1.600 0.294
Nervonic acid  C20:5Δ5,8,11,14,17 0.700±0.280 0.651±0.576 0.438 0.769±0.796 0.664±0.683 0.400
Docosahexanoic acid C22:6Δ4,7,10,13,16,19 3.821±2.826 5.288±2.834 0.196 7.646±2.892 6.641±2.870 0.265
FA concentrations are displayed as mean ± SD. *p<0.05 Control vs AD.
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Although the reason is as yet unclear it could, 
similar to cis-13,16-docosadienoic acid, be 
part of a protective mechanism against AD- 
induced damage. Recent studies show that a 
derivative of DHA, neuroprotectin D1 (NPD1) 
down-regulates beta-amyloid (1-42 triggered 
gene expression of COX-2) n HNG cells [45]. It 
has also been reported that NPD1 affects beta-
amyloid precursor protein processing thus 
reducing beta-amyloid (1-42) synthesis [46]. 
Other LOX-mediated DHA derivatives such as 
17S-resolvins have been shown to reduce infil-
tration of leukocyte and glial cell migration as 
well as their respective cytokine production 
[47]. 
There are several potential explanations for 
increases in the brain levels of some FAs. Firstly 
this could stem directly from the considerable 
loss of brain mass and marked changes in the 
populations of cell types which occurs in late-
stage AD. Notably in AD there is an increased 
loss of neurons with a concomitant increase in 
the levels of astrocytes that ordinarily provide 
numerous levels of support to neurons. Thus 
increases in the levels of some FAs could relate 
to the relatively greater number of astrocytes 
present in AD tissue following severe neuronal 
loss. Therefore, one could hypothesize that the 
elevated FA concentrations as reported herein 
are found to a greater extent in astrocytes. 
Secondly, the relative increase in brain FA con-
tent observed here in late-stage AD could arise 
from processes occurring within the small 
amount of white matter present in each speci-
men. Increase in FA concentrations may also 
result from ceramide accumulation due to the 
activation of the sphingomyelinase in oligoden-
drites which is induced by enhanced beta-amy-
loid peptide levels [48]. Interestingly, our find-
ings correlate with another study which anal-
ysed FA in white matter tissue which reported 
elevated concentrations of palmitoleic acid and 
erucic acid [49]. 
Increased concentrations of other FA observed 
here may be responsible for detrimental effects 
on the brain. For example, both palmitic acid 
and stearic acid have been reported to induce 
hyperphosphorylation of tau proteins and ele-
Figure 3. FA (g/Kg) significantly 
altered between male and female 
subjects with late-stage AD. The 
concentrations of 7 brain FFA were 
significantly affected by gender 
in AD subjects FA concentrations 
are displayed as mean ± SD. 
*p<0.05 was deemed statistically 
significant.
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vate the expression of β-secretase activity in 
embryonic rat cortex cultures [50]. Palmitic 
acid is known to reduce the viability of neuronal 
stem cells and increase apoptotic activity [10]. 
Furthermore, elaidic acid (a ‘trans’ fatty acid) 
appears to drive the oligomerization and aggre-
gation of beta-amyloid, potentially aggravating 
the severity of AD [51]. In conjunction with other 
brain regions that have been studied, palmi-
toleic acid was found to be increased in con-
centration in the Brodmann 7 region of AD 
patients. Astarita et al. reported an increase in 
the same fatty acid concentrations in the hip-
pocampal and the mid frontal cortex regions of 
the brain when controls were compared with 
AD patients [44]. It is also interesting to note 
that in the same study, nervonic acid was found 
to be significantly higher in AD samples in the 3 
various brain regions being studied (mid fron-
tal, hippocampal, and the temporal cortexes) 
[44]. This finding however was in contrast to our 
results as no significant difference (p<0.05) 
was detected. The increase in nervonic acid 
and several other fatty acid concentrations in 
those regions were most likely due to an 
increased stearoyl-Coa desaturase activity 
[44].
It is important for the authors to point out the 
potential limitations of this preliminary investi-
gation. Firstly, although we attempted to clo- 
sely age-match the subjects there is a signifi-
cant difference between groups (P=0.034). 
Secondly, the gender balance of control sub-
jects and AD subjects is not uniform. There is 
potential for age and gender to influence the 
levels of individual fatty acids. Both of these 
confounding factors should be taken into con-
sideration when interpreting the findings.
In conclusion, this study has profiled, identified 
and quantified the widest range of FA detected 
in the Brodmann area 7 brain region of post-
mortem human brain tissue. Significant altera-
tions in several FA were observed in late-stage 
AD. The dramatically increased levels of cis-
Figure 4. Box-and-whisker 
plots of FA (g/Kg) significantly 
altered between male and 
female subjects with late-
stage AD. The concentrations 
of 7 brain FA were significantly 
affected by gender in AD 
subjects FA concentrations 
are displayed as mean ± 
SEM. *p<0.05 was deemed 
statistically significant.
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13,16-docosadienic acid and DHA in AD could 
be part of a neuroprotective anti-inflammatory 
response to AD. Other FA elevations could play 
a role in driving or exacerbating the disease 
pathogenesis. In addition, our study exhibited 
the first gender specific differences with re- 
gards to brain FA concentrations, indicating a 
tendency for FA to be higher in male AD tissue 
than in female AD tissue, a finding which must 
be further investigated in studies with larger 
sample sizes. This study provides an insight 
into changes in lipid metabolism occurring late 
into the development of AD, but it will be neces-
sary to investigate specimens earlier in the 
pathogenesis of AD and also from other types 
of dementia in order to ascertain whether brain 
FA changes are generalized responses to brain 
inflammation or a consequence of neuronal cell 
death. 
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